---
title: 'Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe
  adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation
  trial'
date: '2023-11-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37908361/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231101180626&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: BK-SE36/CpG was well-tolerated and immunogenic. These results
  pave the way for further proof-of-concept studies to demonstrate vaccine ...'
disable_comments: true
---
CONCLUSION: BK-SE36/CpG was well-tolerated and immunogenic. These results pave the way for further proof-of-concept studies to demonstrate vaccine ...